CHRONIC PROSTATITIS COLLABORATIVE CLINICAL RESEARCH STUD

描述(摘自申请人的摘要) 慢性非传染性前列腺炎或慢性盆腔疼痛综合征(CPPS) 代表着临床医学中最大的挑战之一。它包括 一系列症状，这些症状是由 病人和他的医生。这些症状可能包括会阴和大腿疼痛， 阴茎不适，生殖器疼痛，下腰痛，刺激性和梗阻性 排尿症状、射精功能障碍、疲劳和其他各种症状 投诉。治疗通常会导致微小的或间歇性的改善， 频繁的恶化，越来越多的挫折感，以及广泛的使用 资源。在CPPS中，医生和研究人员缺乏明确的认识 在相关的病理生理学和免疫学中，对于什么缺乏共识 构成适当的诊断评估和治疗 管理，在如何最好地量化患者的症状和 由此产生的生活质量影响。这项提案的目标是实现 两个具体项目，解决国家方案规划中目前的知识不足问题。 第一个涉及开发和验证症状指数和 CPPS患者生活质量影响指数。的多中心性质。 该项目将允许创建一种 心理测量学上可靠和有效，但很容易理解和完成 病人。在统一接受的结果衡量标准下，研究人员和 临床医生可以开始使用相同的语言来评估自然 这种疾病的病史及其对各种拟议治疗的反应。 第二个是确定CPPS是否是不适当的伤害反应 在没有持续的细菌伤害的情况下。它将建立信号 调制器，提供新的有效工具来诊断CPPS和 选择并监测个别患者的治疗效果。我们会 研究液体和液体中的生化、细胞和分子标记 细胞表达的前列腺液，并将这些参数与 在第一个项目中制定的成果衡量标准。生物学的 措施将包括对白细胞、一氧化氮、 前列腺液中的活性和荧光原位杂交 前列腺液细胞作为个体免疫细胞类型和免疫标志物的研究 细胞激活。

DESCRIPTION (Taken from the applicant's Abstract) Chronic non-infectious prostatitis or chronic pelvic pain syndrome (CPPS) represents one of the greatest challenges in clinical medicine. It consists of a constellation of symptoms that are subjectively evaluated by both the patient and his physician. These may include perineal and thigh pain, penile discomfort, orchalgia, lower back pain, irritative and obstructive voiding symptoms, ejaculatory dysfunction, fatigue, and a variety of other complaints. Treatments often lead to minimal or intermittent improvement, frequent exacerbations, increasing frustration, and extensive utilization of resources. In CPPS, physicians and researchers lack a clear understanding of the relevant pathophysiology and immunology, lack consensus on what constitutes the appropriate diagnostic evaluation and therapeutic management, and disagree on how best to quantify patients' symptoms and the resulting quality of life impact. The goal of this proposal is to carry out two specific projects that address current knowledge deficits in CPPS. The first involves the development and validation of a symptom index and a quality of life impact index for men with CPPS. The multi-center nature of the project will allow for the creation of an instrument that is psychometrically reliable and valid yet easily understood and completed by patients. With a uniformly accepted outcome measure, researchers and clinicians can begin speaking the same language when assessing the natural history of this disease and its response to various proposed treatments. The second is to determine whether CPPS is an inappropriate injury response in the absence of ongoing bacterial injury. It will establish signal modulators that provide novel and effective tools to diagnose CPPS and to select and monitor treatment efficacy for individual patients. We will study the biochemical, cellular and molecular markers from the fluid and cells of expressed prostatic secretions and correlate these parameters with the outcomes measures developed in the first project. The biological measures will include quantification of white blood cells, nitric oxide activity in prostatic fluid, and fluorescent in situ hybridization of prostate fluid cells for markers of individual immune cell types and immune cell activation.